CClinicalTrials.gg
Active, not recruitingNCT07465328Updated Mar 11, 2026

Studying the Impairment of Stroke and Sarcopenia Patients Using Maximum Voluntary Contractions of the Leg Joints.

An interventional study of MVC measurements of participants in Sarcopenia and Stroke, sponsored by Vrije Universiteit Brussel. Active, not recruiting at 1 site in Belgium. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-11.

Sponsored by Vrije Universiteit Brussel · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Primary completion was expected by Apr 2026, 6 months ago, but the record still lists the study as active, not recruiting.
  • Registered 1 year after the study started (first participant enrolled Feb 2025, registered Mar 2026).
Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this study is to obtain the maximum voluntary torques of the lower-limb joints and to monitor oxygen level in the main lower-limb muscles. This will be done for three joints: i.e. the hip, knee and ankle joint and NIRS sensors will be placed on the biceps femoris, rectus femoris and gastrocnemius muscle. For the hip and knee, the maximum torque will be determined both in exertion direction and flexion direction. For the ankle, both plantarflexion and dorsiflexion will be considered. For each of these directions, the maximum joint torque will be defined for different specific joint angles and joint velocities (see procedure). For every joint and for the whole protocol for the torques measurement campaign, the different muscle of interest will be monitored with the NIRS, i.e. hip is associated with hamstring contraction, knee is associated with thigh contraction and ankle is associated with calf contraction. With these discrete points, an algorithm will be used to obtain a complete plot of the maximum torque in function of both joint angle and joint velocities. Comparing these plots between for example stroke and healthy individuals can help us understand what level of assistance stroke patients require. Comparison in oxygen level between healthy individuals and impairments population of stroke and sarcopenia patients can also help us investigate how oxygen is used depending on the population.

02

Conditions studied

  • Sarcopenia
  • Stroke
03

In context

Sarcopenia

1,208 studies on the registry are indexed under Sarcopenia; 402 are open to participants now.

This study's planned enrollment of 42 is below the median of 60 across 775 interventional studies indexed under Sarcopenia.

Browse Sarcopenia studies →

Lead sponsor

Vrije Universiteit Brussel is the lead sponsor of 154 studies on the registry; 43 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Post stroke patients:

  • Must be 18+ years old
  • Must be three months or more after stroke diagnosis
  • Have difficulties with gait (FAC level 3-4)

Sarcopenia patients:

  • Must be 65+ years old
  • Not be able to perform five chair sit to stands within 15 seconds
  • Grip strength of less than 27 kg for men and less than 16 kg for females
  • Have difficulties with gait (SPPB ≤ 8)

Healthy participants:

  • No physical injuries that limits the torque production in lower-limb joints
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    Measuring MVC's of participants

    Other: MVC measurements of participants

Interventions

  • OtherMVC measurements of participants

    The protocol will be performed for six exertion directions for both legs: Hip Extension (HE), Hip Flexion (HF), Knee Extension (KE), Knee Flexion (KF), Plantar Flexion (PF) and Dorsi Flexion (DF). The protocol will be similar for each of these directions. The protocol described below will be performed for each joint. Position of subject during testing: * Ankle: hip flexed at 80° and knee flexed at 50° (in a seated position) * Knee: hip flexed at 70° (in a seated position) * Hip: done in a standing position. The knee slightly flexed with a knee immobilizer.

06

What researchers measure

Primary outcomes

  1. Obtaining maximum voluntary torques of the lower-limb joints for sarcopenia and stroke patients

    The goal is to determine the maximum torque that each joint can produce in an isostatic case in the sagittal plane. Not only the amount of torque but also at which joint angle this manifests are important parameters that we would like to use for the design process of an exoskeleton. Furthermore, we'd like to obtain the change in maximum torque when transferring from an isostatic test to an isokinetic test. The higher the joint velocity, the more the torque will decrease. However, how much is this decrease? We expect that the decrease for increased joint velocities in the targeted populations will differ compared to healthy individuals

    Time frame: 2 years

Secondary outcomes

  1. Measuring muscle oxygenation

    To determine the differences in oxygen delivery and consumption between healthy individuals, sarcopenia patients, and stroke patients. Studying these profiles will provide insights into how these impairments affect the muscle under investigation and how oxygenation dynamics behave throughout the experiment.

    Time frame: 2 years

07

Study locations

1 site
  • Vrije Universiteit Brussel
    Brussels, 1050, Belgium
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07465328
Lead sponsor
Vrije Universiteit Brussel
Responsible party
Sponsor
First posted
Mar 11, 2026
Start date
Feb 11, 2025
Primary completion
Apr 1, 2026 (estimated)
Completion
Feb 11, 2027 (estimated)
Last update
Mar 11, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion